Which process are you using to help patients
get started?
CoverMyMeds®
Complete Prior Authorization (PA) request via CoverMyMeds (CMM) account
NO PAPER. NO FAX. NO DUPLICATE SERVICES.
If PA approved
If PA denied
Transfer prescription to payer-preferred Specialty Pharmacy for delivery
Eligible† commercially insured patients can activate via COSENTYX.com or by calling 1-844-COSENTYX (1-844-267-3689)
If the PA request was initiated by the Specialty Pharmacy, CMM will notify them of the approval so the pharmacy can schedule delivery with the patient
To sign in or create an account, visit covermymeds.com
To sign in or create an account, visit covermymeds.com
Services provided by
CoverMyMeds
- Complete PA requests in minutes and get a response as quickly as a few hours
- Electronic patient signatures
- Automatic handoff to Covered Until You’re Covered Program‡ for eligible patients and enrollment into COSENTYX® Connect to be paired with a COSENTYX® Connect Team Member
- Case support from CMM agents keep you up to date
While coverage is being pursued, submit a Start Form to the Covered Until You’re Covered Program through your CMM account to enroll patients in
FREE COSENTYX for up to 2 years for eligible† commercially insured patients while coverage is pursued‡
Check all appropriate boxes on the form for access to COSENTYX® Connect offerings
To sign in or create an account, visit covermymeds.com
Services provided by
CoverMyMeds
- Complete PA requests in minutes and get a response as quickly as a few hours
- Electronic patient signatures
- Automatic handoff to Covered Until You’re Covered Program‡ for eligible patients and enrollment into COSENTYX® Connect to be paired with a COSENTYX® Connect Team Member
- Case support from CMM agents keep you up to date
Specialty Pharmacies
Regardless of Specialty Pharmacy, ALL patients may self-enroll into the COSENTYX® Connect Personal Support Program
Send COSENTYX prescription to the Specialty Pharmacy of choice
If PA approved
If PA denied
Specialty Pharmacy dispenses COSENTYX to the patient
Eligible† commercially insured patients can activate via COSENTYX.com or by calling 1-844-COSENTYX (1-844-267-3689)
Novartis does not recommend the use of any particular Specialty Pharmacy.
While coverage is being pursued, submit a Start Form to COSENTYX® Connect for enrollment into
FREE COSENTYX for up to 2 years for eligible† commercially insured patients while coverage is pursued‡
Novartis does not recommend the use of any particular Specialty Pharmacy.
COSENTYX® Connect
Ensure ALL consent boxes are checked on the form to get full COSENTYX® Connect services
Access & Reimbursement Manager (ARM) Support
COSENTYX® Connect Team Member
Auto-enroll in COSENTYX® Connect Personal Support Program & $0 co-pay, if eligible
Send completed Start Form via fax (with patient and provider signatures and dates)
Support provided during benefits investigation, PA, and up to 2 levels of appeal. Fax communications keep the office informed every step of the way.
If PA approved
If PA denied
Rx transferred to payer-preferred Specialty Pharmacy for delivery
Check the box on the Start Form to ensure $0 co-pay for eligible† commercially insured patients is activated
While coverage is being pursued, eligible† patients are auto-enrolled in
FREE COSENTYX for up to 2 years for eligible† commercially insured patients while coverage is pursued‡
*Limitations apply. Up to a $16,000 annual limit. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. Limitations may apply in MA and CA. For complete Terms & Conditions details, call 1-844-267-3689.
†Certain payers have carve-outs that restrict utilization of manufacturer support programs.
‡The Covered Until You're Covered Program is available for COSENTYX subcutaneous injection only. Eligible patients must have commercial insurance, a valid prescription for COSENTYX, and a denial of insurance coverage based on a prior authorization request. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment in order to remain eligible. Program provides COSENTYX for free to eligible patients for up to two years, or until they receive insurance coverage approval, whichever occurs earlier. A valid prescription consistent with FDA-approved labeling is required. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. Enrolled patients awaiting coverage for COSENTYX after two years may be eligible for a limited Program extension. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.
CoverMyMeds is a registered trademark of CoverMyMeds LLC. All rights reserved.
FDA, US Food and Drug Administration; PA, prior authorization; Rx, prescription.
7/23 285704
INDICATIONS
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
WARNINGS AND PRECAUTIONS
Infections
INDICATIONS
COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.
COSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in patients 2 years of age and older.
COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis (AS).
COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX. Cases of anaphylaxis have been reported during treatment with COSENTYX.
WARNINGS AND PRECAUTIONS
Infections
COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in COSENTYX treated subjects compared to placebo-treated subjects. In placebo-controlled clinical trials in subjects with moderate to severe plaque psoriasis, higher rates of common infections, such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%) and mucocutaneous infections with candida (1.2% versus 0.3%) were observed with COSENTYX compared with placebo. A similar increase in risk of infection was seen in placebo-controlled trials in subjects with psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. The incidence of some types of infections appeared to be dose-dependent in clinical studies. In the postmarketing setting, serious and some fatal infections have been reported in patients receiving COSENTYX.
Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection.
Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves.
Pre-treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Avoid administration of COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients closely for signs and symptoms of active TB during and after treatment.
Inflammatory Bowel Disease
Caution should be used when prescribing COSENTYX to patients with inflammatory bowel disease. Exacerbations, in some cases serious, occurred in COSENTYX treated subjects during clinical trials in plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. In addition, new onset inflammatory bowel disease cases occurred in clinical trials with COSENTYX. In an exploratory trial in 59 subjects with active Crohn’s disease, there were trends toward greater disease activity and increased adverse events in the secukinumab group as compared to the placebo group. Patients who are treated with COSENTYX should be monitored for signs and symptoms of inflammatory bowel disease.
Eczematous Eruptions
In postmarketing reports, cases of severe eczematous eruptions, including atopic dermatitis-like eruptions, dyshidrotic eczema, and erythroderma, were reported in patients receiving COSENTYX; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of COSENTYX.
Treatment may need to be discontinued to resolve the eczematous eruption. Some patients were successfully treated for eczematous eruptions while continuing COSENTYX.
Hypersensitivity Reactions
Anaphylaxis and cases of urticaria occurred in COSENTYX treated subjects in clinical trials. If an anaphylactic or other serious allergic reaction occurs, administration of COSENTYX should be discontinued immediately and appropriate therapy initiated.
The removable caps of the COSENTYX Sensoready® pen and the COSENTYX 1 mL and 0.5 mL prefilled syringes contain natural rubber latex, which may cause an allergic reaction in latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.
Immunizations
Prior to initiating therapy with COSENTYX, consider completion of all age appropriate immunizations according to current immunization guidelines. COSENTYX may alter a patient’s immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX.
MOST COMMON ADVERSE REACTIONS
Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.
Please see full Prescribing Information, including Medication Guide.